Tailor-made Antibodies
and Tools for Life Science
Home|||||Technical Support

EAAT2 peptide extracellular domain - 250-2P

EAATs are transmembrane proteins involved in the removal of extracellular glutamate
control peptide
Cat. No.: 250-2P
Amount: 100 µg
Price: $105.00
Cat. No. 250-2P 100 µg peptide, lyophilized. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Control peptides should be stored at -20°C when still lyophilized!
Applications
 
Immunogen Synthetic peptide corresponding to AA 146 to 161 from mouse EAAT2 (UniProt Id: P43006)
Recommended dilution Optimal concentrations should be determined by the end-user.
Matching antibodies 250 203, 250 204
Remarks

This control peptide consists of the synthetic peptide (aa 146 - 161 of mouse EAAT 2) that has been used for immunization. It has been tested in preadsorption experiments and blocks efficiently and specifically the corresponding signal in Western blots. The amount of peptide needed for efficient blocking depends on the titer and on the affinity of the antibody to the antigen.

Data sheet 250-2p.pdf
Cat. No.: 250-2P
Amount: 100 µg
Price: $105.00
Background
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. After the release of glutamate from synaptic vesicles into the synaptic cleft during neurotransmission, excitatory amino acid transporters (EAATs) remove extracellular glutamate to avoid excitotoxic levels.
Five EAATs with differential expression patterns have been described so far: EAAT 1, also referred to as GLAST and SLC1A3, has neuroprotective potential following ischemia and is expressed by reactive astrocytes and activated microglia. EAAT 2 (GLT-1, SLC1A2) is the most abundant and primarily expressed in astrocytes. EAAT 3 / SLC1A1 is expressed in neurons and has also been shown to be involved in the uptake of extracelluar cysteine. EAAT 4 shows weak expression in the forebrain and high levels in Purkinje cells of the cerebellum. EAAT 5 has only been described for humans and is primarily expressed in the retina.
Protocols